CORAL GABLES, Fla., March 11, 2019 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX),
a biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating,
chronic neuromuscular and neurological diseases, today announced that it will release fourth quarter and year end 2018 financial
results after market close on Monday, March 18, 2019. Further, Catalyst management will host an investment-community
conference call at 8:30 a.m. ET on Tuesday, March 19, 2019 to discuss the financial results and to provide a
corporate update.
Investors who wish to participate in the conference call may do so by dialing (877) 407-8912 for domestic and
Canadian callers or (201) 689-8059 for international callers. Those interested in listening to the conference call live via the
internet may do so by visiting the Investors page of the company's website at www.catalystpharma.com and clicking on the webcast link on the Investors home page.
A webcast replay will be available on the Catalyst website for 30 days following the call by visiting the
Investor page of the company's website at www.catalystpharma.com.
About Catalyst Pharmaceuticals
Catalyst Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative
therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, including Lambert-Eaton myasthenic
syndrome (LEMS), congenital myasthenic syndromes (CMS), MuSK antibody positive myasthenia gravis (MuSK-MG) and spinal muscular
atrophy (SMA) Type 3. Catalyst's new drug application for Firdapse® (amifampridine) 10 mg tablets for the treatment of adults
with LEMS was recently approved by the U.S. Food & Drug Administration ("FDA"), and Firdapse is now commercially
available in the United States. Prior to its approval, Firdapse for LEMS had received breakthrough therapy designation and
orphan drug designation from the FDA.
Firdapse is currently being evaluated in clinical trials for the treatment of CMS, MuSK-MG and SMA Type 3 and
has received Orphan Drug Designation from the FDA for CMS and myasthenia gravis. Firdapse (amifampridine) 10 mg tablets
is the first and only approved drug in Europe for the symptomatic treatment in adults with LEMS.
Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements involve known and unknown
risks and uncertainties, which may cause Catalyst's actual results in future periods to differ materially from forecasted results.
A number of factors, including (i) whether Catalyst will be successful in commercializing Firdapse (ii) whether, even if Catalyst
is successful in commercializing Firdapse, Catalyst will become profitable, (iii) whether Firdapse will ever be approved for the
treatment of CMS, MuSK-MG, SMA Type 3, or any other disease, and (iv) those other factors described in Catalyst's Annual Report on
Form 10-K for the fiscal year 2017 and its other filings with the U.S. Securities and Exchange Commission (SEC), could adversely
affect Catalyst. Copies of Catalyst's filings with the SEC are available from the SEC, may be found on Catalyst's website, or may
be obtained upon request from Catalyst. Catalyst does not undertake any obligation to update the information contained herein,
which speaks only as of this date.
Investor Contact Brian Korb Solebury Trout (646) 378-2923 bkorb@troutgroup.com Company Contact Patrick J. McEnany Catalyst Pharmaceuticals Chief Executive Officer (305) 420-3200 pmcenany@catalystpharma.com Media Contact David Schull Russo Partners (212) 845-4271 david.schull@russopartnersllc.com